Innovent Biologics Inc (IVBIY)
19.48
0.00 (0.00%)
USD |
OTCM |
May 16, 16:00
Innovent Biologics Total Liabilities (Quarterly): 1.143B for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.143B |
| June 30, 2023 | 980.70M |
| June 30, 2023 | 980.70M |
| December 31, 2022 | 994.14M |
| June 30, 2022 | 979.97M |
| June 30, 2022 | 979.97M |
| December 31, 2021 | 927.71M |
| June 30, 2021 | 703.97M |
| June 30, 2021 | 703.97M |
| December 31, 2020 | 467.64M |
| Date | Value |
|---|---|
| June 30, 2020 | 359.55M |
| June 30, 2020 | 359.55M |
| December 31, 2019 | 353.65M |
| June 30, 2019 | 301.52M |
| June 30, 2019 | 301.52M |
| December 31, 2018 | 278.84M |
| June 30, 2018 | 975.77M |
| June 30, 2018 | 975.77M |
| December 31, 2017 | 624.83M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
301.52M
Minimum
Jun 2019
1.143B
Maximum
Dec 2023
702.48M
Average
703.97M
Median
Jun 2021
Total Liabilities (Quarterly) Benchmarks
| Sinovac Biotech Ltd | 1.635B |
| CASI Pharmaceuticals Inc | 51.10M |
| Zai Lab Ltd | 226.27M |
| Gracell Biotechnologies Inc (DELISTED) | 36.85M |
| Adagene Inc | 45.17M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.910B |
| Shareholders Equity (Quarterly) | 1.767B |
| Debt to Equity Ratio | 0.2811 |
| Current Ratio | 3.000 |
| Net Debt Paydown Yield | -0.39% |